Authors:
Dittmann, H
Sokler, M
Kollmannsberger, C
Dohmen, BM
Baumann, C
Kopp, A
Bares, R
Claussen, CD
Kanz, L
Bokemeyer, C
Citation: H. Dittmann et al., Comparison of (18)FDG-PET with CT scans in the evaluation of patients withresidual and recurrent Hodgkin's lymphoma, ONCOL REP, 8(6), 2001, pp. 1393-1399
Authors:
Kuczyk, MA
Bokemeyer, C
Hartmann, J
Schubach, J
Walter, C
Machtens, S
Knuchel, R
Kollmannsberger, C
Jonas, U
Serth, J
Citation: Ma. Kuczyk et al., Predictive value of altered p27(Kip1) and p21(WAF/Cip1) protein expressionfor the clinical prognosis of patients with localized prostate cancer, ONCOL REP, 8(6), 2001, pp. 1401-1407
Authors:
Kollmannsberger, C
Mayer, F
Kuczyk, M
Kanz, L
Bokemeyer, C
Citation: C. Kollmannsberger et al., Treatment of patients with metastatic germ cell tumors relapsing after high-dose chemotherapy, WORLD J URO, 19(2), 2001, pp. 120-125
Authors:
Machtens, S
Serth, J
Bokemeyer, C
Bathke, W
Minssen, A
Kollmannsberger, C
Hartmann, J
Knuchel, R
Kondo, M
Jonas, U
Kuczyk, M
Citation: S. Machtens et al., Expression of the p53 and maspin protein in primary prostate cancer: Correlation with clinical features, INT J CANC, 95(5), 2001, pp. 337-342
Authors:
Kollmannsberger, C
Gerl, A
Schleucher, N
Beyer, J
Kuczyk, M
Rick, O
Gasper, J
Sosada, M
Rie, C
Kanz, L
Bokemeyer, C
Citation: C. Kollmannsberger et al., Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer, ANTI-CANC D, 11(7), 2000, pp. 535-539
Authors:
Kollmannsberger, C
Nichols, C
Meisner, C
Mayer, F
Kanz, L
Bokemeyer, C
Citation: C. Kollmannsberger et al., Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: An explorative analysis using cart modeling, ANN ONCOL, 11(9), 2000, pp. 1115-1120
Authors:
Kollmannsberger, C
Nichols, C
Bamberg, M
Hartmann, JT
Schleucher, N
Beyer, J
Schoffski, P
Derigs, G
Ruther, U
Bohlke, I
Schmoll, HJ
Kanz, L
Bokemeyer, C
Citation: C. Kollmannsberger et al., First-line high-dose chemotherapy +/- radiation therapy in patients with metastatic germ-cell cancer and brain metastases, ANN ONCOL, 11(5), 2000, pp. 553-559
Citation: C. Kollmannsberger et C. Bokemeyer, Therapy-related leukemia following high-dose chemotherapy: Compensating for the benefit?, ONKOLOGIE, 23(5), 2000, pp. 480-482
Authors:
Kollmannsberger, C
Quietzsch, D
Haag, C
Lingenfelser, T
Schroeder, M
Hartmann, JT
Baronius, W
Hempel, V
Clemens, M
Kanz, L
Bokemeyer, C
Citation: C. Kollmannsberger et al., A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer, BR J CANC, 83(4), 2000, pp. 458-462
Authors:
Hartmann, JT
Quietzsch, D
Daikeler, T
Kollmannsberger, C
Mayer, F
Kanz, L
Bokemeyer, C
Citation: Jt. Hartmann et al., Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer, ANTI-CANC D, 10(8), 1999, pp. 729-733
Authors:
Kollmannsberger, C
Brugger, W
Hartmann, JT
Maurer, F
Bohm, P
Kanz, L
Bokemeyer, C
Citation: C. Kollmannsberger et al., Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma, ANTI-CANC D, 10(5), 1999, pp. 453-456
Authors:
Kollmannsberger, C
Pressler, H
Mayer, F
Kanz, L
Bokemeyer, C
Citation: C. Kollmannsberger et al., Cisplatin-refractory, HER2/neu-expressing germ-cell cancer: Induction of remission by the monoclonal antibody Trastuzumab, ANN ONCOL, 10(11), 1999, pp. 1393-1394
Authors:
Bokemeyer, C
Kollmannsberger, C
Meisner, C
Harstrick, A
Beyer, J
Metzner, B
Hartmann, JT
Schmoll, HL
Einhorn, L
Kanz, L
Nichols, C
Citation: C. Bokemeyer et al., First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis, J CL ONCOL, 17(11), 1999, pp. 3450-3456
Authors:
Hartmann, JT
Kuczyk, MA
Kollmannsberger, C
Kanz, L
Bokemeyer, C
Citation: Jt. Hartmann et al., Future prospects in the chemotherapy of metastatic nonseminomatous testicular germ-cell cancer, WORLD J URO, 17(5), 1999, pp. 324-333
Authors:
Kollmannsberger, C
Mross, K
Jakob, A
Kanz, L
Bokemeyer, C
Citation: C. Kollmannsberger et al., Topotecan - A novel topoisomerase I inhibitor: Pharmacology and clinical experience, ONCOL-BASEL, 56(1), 1999, pp. 1-12
Authors:
Hartmann, JT
Kollmannsberger, C
Kanz, L
Bokemeyer, C
Citation: Jt. Hartmann et al., Platinum organ toxicity and possible prevention in patients with testicular cancer, INT J CANC, 83(6), 1999, pp. 866-869
Authors:
Hartmann, JT
Albrecht, C
Schmoll, HJ
Kuczyk, MA
Kollmannsberger, C
Bokemeyer, C
Citation: Jt. Hartmann et al., Long-term effects on sexual function and fertility after treatment of testicular cancer, BR J CANC, 80(5-6), 1999, pp. 801-807
Citation: C. Bokemeyer et al., The potential role of topotecan in the treatment of pediatric and adult soft-tissue sarcomas, ONKOLOGIE, 21, 1998, pp. 32-36